Top Eight Asia Biopharma Clusters 2017 | The Lists

Even in a down year, Asia’s biotech industry outperformed the U.S. in one key measure. As noted in the latest edition of EY’s annual “Beyond Borders” report, biotechs in China, Japan, Singapore, South Korea, and Taiwan combined to raise more than $2.5 billion in overall financing—30% below the $3 billion-plus racked up in 2015. Last year’s shrinking IPO market and a decline in follow-on financings and other fundings of publicly-traded biotechs more than negated an 11% increase in venture capital (VC) financing.

However, Asia’s year-to-year decline is smaller than that of the U.S., where biotech financing fell in 2016 by 45% (to $34.2 billion) paced by its own declines in IPOs (64% less in proceeds) and follow-on financings (down 49%)—the result of investor skittishness about the U.S. presidential election—and even VC financing (down…

Complete article from the original source…

Reply